Choose the only SMA gene replacement therapy for children less than 2 years old
Matteo has 2 copies of SMN2 gene
Treated at ~1 month old
ZOLGENSMA stops the progression of spinal muscular atrophy (SMA) by helping children meet milestones, like sitting, standing, walking on their own, and more.*
ZOLGENSMA is a prescription gene replacement therapy for the treatment of SMA in children less than 2 years old.
*Results and outcomes vary among children based on several factors, including how far their SMA symptoms progressed prior to receiving treatment.
ZOLGENSMA—Over 9 years of follow-up data for children with SMA
Want to know more about ZOLGENSMA?
Learn how ZOLGENSMA targets the root cause of SMA with a one-time dose.
Curious about the ZOLGENSMA treatment experience?
Early treatment is important. Learn how to get started with ZOLGENSMA.
Aniya has 4 copies of SMN2.
See how her family pushed for early treatment and how that made a big difference
Before receiving treatment with ZOLGENSMA, Aniya received another SMA treatment
Novartis Patient Support™
Guidance for families from the moment they choose ZOLGENSMA—including understanding insurance and life after treatment—answering questions along the way